Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Bioinformatic prediction and coexpression network identifies repurposed novel drugs for papillary thyroid cancer
Download
HIBIT22_paper_78.pdf
Date
2022-10
Author
Temiz, Kubra
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
377
views
56
downloads
Cite This
Thyroid cancer is a type of cancer that affects the endocrine system and has a high malignancy. Papillary thyroid cancer, the most common subtype of thyroid cancer, also has well-differentiated features. Early diagnosed and well-differentiated thyroid cancer is generally associated with a good prognosis and/or survival rate. Therefore, it is of great importance to determine the molecular signatures of the disease. In this study, five papillary thyroid cancer-related gene expression datasets were analyzed using linear models for microarray data (LIMMA) method. Differentially expressed genes (DEG) have been identified and gene set enrichment analysis was performed via ConsensusPathDB and the MetaScape tool. Coexpression network was constructed by using mutual DEG expression profiles and network modules were found a disease module with 21 nodes, 145 edges, 69% density, and significantly correlated genes in all datasets was obtained compared with normal thyroid tissues. Genes in the disease module were processed in L1000CDS2, resulting in 42 drug lists and identified as drug repurposing candidates, and text mining analyzes was performed by using Python library urllib3. Doxorubicin hydrochloride, doxorubicin, and Dorsomorphin dihydrochloride drugs with the highest TF-IDF are already used in the treatment of thyroid cancer. FDA-approved AS605240, piperlongumine, and TWS119 drugs and/or small molecules that are not used in thyroid cancer have been identified as candidate drugs that can be used in the treatment of thyroid cancer. As a result of FDA-approved drugs piperlongumine, and TWS119 may be promising candidates for thyroid cancer. Preclinical testing, as well as additional drug validation, may ensure new cure preference for thyroid cancer.
Subject Keywords
Drug repurposing
,
Papillary thyroid cancer
,
Coexpression network
,
Gene expression
URI
https://hibit2022.ims.metu.edu.tr
https://hdl.handle.net/11511/101904
Conference Name
The International Symposium on Health Informatics and Bioinformatics
Collections
Graduate School of Informatics, Conference / Seminar
Suggestions
OpenMETU
Core
Synthesis of poly (dl-lactic-co-glycolic acid) coated magnetic nanoparticles for anti-cancer drug delivery
Tansık, Gülistan; Gündüz, Ufuk; Department of Biology (2012)
One of the main problems of current cancer chemotherapy is the lack of selectivity of anti-cancer drugs to tumor cells which leads to systemic toxicity and adverse side effects. In order to overcome these limitations, researches on controlled drug delivery systems have gained much attention. Nanoscale based drug delivery systems provide tumor targeting. Among many types of nanocarriers, superparamagnetic nanoparticles with their biocompatible polymer coatings can be targeted to an intented site by an extern...
Microarray applications for determination of the effects of emodin on breast cancer cell lines
Ekenel Qomi, Emilia; İşcan, Mesude; Çoruh, Nursen; Department of Biotechnology (2011)
Cancer is a genetic disease that is characterized by uncontrolled cells growth. Breast cancer is a type of cancer originating from breast tissue. Some breast cancers are sensitive to hormones such as estrogen which makes it possible to treat them by blocking the effects of these hormones in the target tissues. These require less aggressive treatment than hormone negative cancers. Breast cancers without hormone receptors, are higher-risk, and are treated more aggressively. The aim of our study is to investig...
Nuclear Deformability of Breast Cells Analyzed from Patients with Malignant and Benign Breast Diseases
Antmen, Ezgi; Ermiş Şen, Menekşe; Kuren, Ozgur; Beksac, Kemal; Irkkan, Cigdem; HASIRCI, Vasıf Nejat (2023-03-13)
Breast cancer is a heterogeneous and dynamic disease, in which cancer cells are highly responsive to alterations in the microenvironment. Today, conventional methods of detecting cancer give a rather static image of the condition of the disease, so dynamic properties such as invasiveness and metastasis are difficult to capture. In this study, conventional molecular-level evaluations of the patients with breast adenocarcinoma were combined with in vitro methods on micropatterned poly(methyl methacrylate) (PM...
Metastatic behaviour of doxorubicin resistant MCF-7 breast cancer cells after Vimentin silencing
Tezcan, Okan; Gündüz, Ufuk; Department of Biology (2013)
Chemotherapy is one of the common treatments in cancer therapy. The effectiveness of chemotherapy is limited by several factors one of which is the emergence of multidrug resistance (MDR). MDR is caused by the activity of diverse ATP binding cassette (ABC) transporters that pump drugs out of the cells. There are several drugs which have been used in treatment of cancer. One of them is doxorubicin that intercalates and inhibits DNA replication. However, doxorubicin has been found to cause development of MDR ...
Network-based discovery of molecular targeted agent treatments in hepatocellular carcinoma
Fayetörbay, Rumeys; Tunçbağ, Nurcan; Department of Bioinformatics (2020)
Hepatocellular carcinoma (HCC) is one of the most-deadly cancers and the most common type of primary liver cancer. Multikinase inhibitor Sorafenib is one of FDA approved targeted agents in HCC treatment. PI3K/AKT/mTOR pathway is altered in about 51% of HCC; hence, understanding how Sorafenib and PI3K/AKT/mTOR pathway inhibitors act at signaling level is crucial for targeted therapies and to reveal the off-target effects. In this work, we use gene expression profiles (GEPs) of HCC cells (Huh7 and Mahlavu) wh...
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
K. Temiz, “Bioinformatic prediction and coexpression network identifies repurposed novel drugs for papillary thyroid cancer,” Erdemli, Mersin, TÜRKİYE, 2022, p. 3078, Accessed: 00, 2023. [Online]. Available: https://hibit2022.ims.metu.edu.tr.